- ￥5000
- GeneTex
- 美国
- GTX02130
- 2025年07月15日
- Neutralizing/Inhibition
- Mouse
- Human
企业认证
相关产品推荐更多 >
![AKT antibody [N2C2], Internal](https://img1.dxycdn.com/2022/0328/928/5237890237314300453-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human IL-6R / CD126 protein
- 亚型：
IgG1
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Human
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
Human
- 目录编号：
GTX02130
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Mouse
- 应用范围：
Neutralizing/Inhibition
- 浓度：
Batch dependent (Please refer to the vial label for the specific concentration.)
- 靶点：
We do not recommend use of this product for Dog,Mouse,Rat.
- 抗体英文名：
IL6 Receptor antibody [3H7D3H1]
- 抗体名：
IL6 Receptor 抗体 [3H7D3H1]
- 规格：
200 μg
Enhancement of recombinant human IL6 protein (100 ng/ml) activity (IL6-dependent inhibition of cell Proliferation activity) elicited by recombinant human IL-6 Rα protien (50 ng/ml) in M1 cells is neutralized by increasing concentrations of GTX02130 IL6 Receptor antibody [3H7D3H1].
IC₅₀ : 0.15-0.6 μg/ml.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Aspects of CNS Lupus: Mouse Models of Anti-NMDA Receptor Antibody Mediated Reactivity
of interest binds the N -methyl-d -aspartate receptor (NMDAR), a receptor for glutamate that is a major excitatory neurotransmitter in the brain involved in synaptic plasticity, in memory and learning, and in emotional responses. We introduce basic
This work describes protocols for the production of single-chain antibody and T-cell receptor fragments inE. coli . A choice of methods is given for the purification of the recombinant fragments that rely on the use of either immunoaffinity
Antibody Targeted siRNA Delivery
only. The commercial success of in vivo applications of RNAi hinges on the development of new delivery methods. Our strategy involves the use of antibody-based delivery agents to target and deliver siRNA into specific cell types. We have developed antibody-based agents
技术资料暂无技术资料 索取技术资料
